Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008

ncludes amortization expense related to purchased intangible assets

as well as amortization of the inventory step-up related to the

acquisition of the former Merck Generics business.

(3) Integration and other non-recurring expenses include charges

principally related to the acquisition and integration of the former

Merck Generics business (e.g., non-recurring professional and

consulting fees, retention and other non-recurring expenses).

(4) The tax effect is calculated assuming an annual effective tax rate for

the resulting adjusted earnings. This tax effect adjustment results in

an effective tax rate on adjusted earnings that approximates 38%

before the impact of any tax synergies.

Below is a reconciliation of GAAP net earnings (loss) to adjusted EBITDA for the three and nine months ended Sept. 30, 2008:

Three months ended Nine months ended

($'s in millions) September 30, 2008 September 30, 2008

GAAP net earnings (loss) $206.8 $(176.0)


Minority interest (0.2) (2.3)

Income from equity method

investees (0.5) (3.2)

Income taxes 272.4 197.4

Interest expense 87.6 264.8

Depreciation & amortization 131.5 417.4

EBITDA 697.6 698.1

Add/(Deduct) Adjustments:

Non-cash stock-based

compensation expense 7.6 23.2

Bystolic revenues (455.0) (468.1)

Integration and other non-

recurring expenses 26.8 91.3

Goodwill impairme

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
(Date:8/23/2014)... August 23, 2014 Dr. ... LLC announced today that Janet B. Arrowsmith, MD, ... consultant. NDA Partners Premier Experts are top tier ... to bring extraordinary value to the company’s clients. ... solutions to help clients successfully develop their medical ...
(Date:8/22/2014)... August 23, 2014 This is ... state of the Papain industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/22/2014)... August 22, 2014 Today the Academy of ... United States Court of Appeals for the D.C. Circuit challenging ... published in the Federal Register on June 25, 2014. ... contrary to the text and intent of the FAA Modernization ... Congress’ specific prohibition on any new rules or regulations regarding ...
(Date:8/22/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have been ... June 30, , Six-months ended June 30, ( in ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 , ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Accera Inc., a privately,held biotechnology company focused on ... it has appointed William,T. Poncy, M.B.A., as vice ... commercial launch of Ketasyn (AC-1202) as a medical ... Alzheimer,s disease. "Given his strong track record ...
... Assay Development, Biomarker Identification ... and ADME/Tox Applications, ... MCET), entered into a worldwide,exclusive license and technology purchase agreement ... human liver cell lines. Corning paid MultiCell a license ...
... Alliance, the leading,management consulting firm specializing in the pharmaceutical ... as one of the best,places to work in the ... Business Journal, ranking third among midsize companies. The award,was ... annual Best,Places to Work luncheon and awards ceremony on ...
Cached Biology Technology:Accera, Inc. Names William T. Poncy Vice President of Commercial Development 2Accera, Inc. Names William T. Poncy Vice President of Commercial Development 3MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3Campbell Alliance Named 'Best Place to Work' by Triangle Business Journal 2
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... Markets ( ) has announced the ... North America 2014-2018"  report to their ... , , ,Biometrics is a technology ... individuals based on their physical or ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... 2013) The world,s leading conservation organizations have joined together ... eastern lowland gorilla ( Gorilla beringei graueri ). Found ... Democratic Republic of Congo (DRC), Grauer,s gorilla is not only ... largest primate in the world. With their entire range ...
... advance toward overcoming a major barrier to tapping the ... medicine in developing new and more effective modern drugs. ... Information and Modeling . Andreas Bender and ... modern medicine. In the world,s largest international clinical trial, ...
... World, the first international conference examining the critical link ... the University of Pennsylvania from Wednesday, March 13, through ... Penn Institute for Urban Research (Penn IUR), in partnership ... Steering Committee representing nine schools and six centers, is ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3Penn conference tackles complex relationship between urbanization and food 2
... Construction KitTM allows graphic manipulation of DNA ... has an award winning interface design that ... addition to providing sophisticated drawing capabilities for ... the "Best Plasmid Mapping Software" by the ...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Biology Products: